| Literature DB >> 23259665 |
Alessandra Fiorentini1, Nicola Petrosillo, Angelo Di Stefano, Stefania Cicalini, Laura Borgognoni, Evangelo Boumis, Luigi Tubani, Pierangelo Chinello.
Abstract
BACKGROUND: Aim of the study was to assess QTc interval by a 24-hour ECG recording in a group of HIV-infected individuals with a basal prolonged QTc. The risk factors associated with QTc prolongation and the indices of cardiovascular autonomic control were also evaluated.Entities:
Mesh:
Year: 2012 PMID: 23259665 PMCID: PMC3543166 DOI: 10.1186/1471-2261-12-124
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Figure 1Algorithm of the study.
Demographic and clinical features of cases and controls
| Gender M | 23 (72%) | 46 (72%) | 0.8 |
| Age (years)* | 45.7±7.6 | 45±9.9 | 0.6 |
| BMI ≥25 | 15 (47%) | 22 (34%) | 0.3 |
| < 25 | 17 (53%) | 42 (66%) | |
| CDC stage A+B | 22 (69%) | 46 (72%) | 0.9 |
| C | 10 (31%) | 18 (28%) | |
| Years since HIV diagnosis* | 10.9±7.1 | 7.8±6.4 | 0.04 |
| Risk factors for HIV infection | |||
| IVDU | 8 (25%) | 10 (16%) | 0.3 |
| MSM | 7 (22%) | 19 (30%) | |
| Eterosexual | 16 (50%) | 35 (54%) | |
| other | 1 (3%) | 0 | |
| Arterial hypertension | 4 (12%) | 13 (20%) | 0.5 |
| Current smokers | 18 (56%) | 36 (56%) | 0.8 |
| Diabetes | 0 | 0 | |
| Hypertriglyceridaemia | 7 (22%) | 17 (26%) | 0.8 |
| Hypercholesterolaemia | 7 (22%) | 18 (28%) | 0.7 |
| Alcohol abuse | 5 (16%) | 3 (5%) | 0.1 |
| Familiarity for IHD | 10 (31%) | 23 (40%) | 0.8 |
| Waist circumference (cm)* | 90.6±12.5 | 87.0±10.0 | 0.16 |
| Hip circumference (cm)* | 97.3±10.4 | 96.0±6.9 | 0.5 |
| Waist/hip ratio* | 0.93±0.07 | 0.90±0.07 | 0.05 |
| Active drug abuse | 3 (9%) | 3 (5%) | 0.4 |
| Methadone therapy | 2 (6%) | 3 (5%) | 1 |
| Prophylaxis with cotrimoxazole | 3 (9%) | 8 (12%) | 0.7 |
| Ongoing ART | 28 (87%) | 53 (83%) | 0.7 |
| Type of ART | |||
| -PI-based | 12 (37%) | 26 (41%) | 0.4 |
| -NNRTI-based | 13 (41%) | 25 (39%) | |
| -3 NRTI | 3 (9%) | 2 (3%) | |
| HCV positive | 8 (25%) | 12 (19%) | 0.6 |
| HBsAg positive | 1 (3%) | 1 (2%) | 1 |
| Na (mEq/L)* | 139±3.2 | 139±3.9 | 1 |
| K (mEq/L)* | 4,2±0.4 | 4,3±0.3 | 0.2 |
| Ca (mg/dL)* | 9,2±0.6 | 9,1±0.5 | 0.4 |
| CD4+ lymphocytes/mmc* | 501±214 | 490±264 | 0.8 |
| HIVRNA (cp/mL) | |||
| <50 | 23 (72%) | 45 (70%) | 0.9 |
| ≥50 | 9 (28%) | 19 (30%) | |
| QTc interval (ms)* | 475±33 | 401±23 | <0.0001 |
| Ectopic ventricular beats | 13 (41%) | 17 (26%) | 0.2 |
| Ectopic supraventricular beats | 14 (44%) | 30 (47%) | 0.9 |
*: mean±SD; BMI: body mass index; IVDU: intravenous drug users; MSM: men having sex with men; IHD: ischaemic heart disease; ART: antiretroviral therapy; PI: protease inhibitors; NNRTI: non-nucleoside reverse transcriptase inhibitors; NRTI: nucleoside reverse transcriptase inhibitors.
Antiretroviral drugs and QTc prolongation
| Zidovudine | |||
| Yes | 11 | 12 | 0.15 |
| No | 21 | 52 | |
| Lamivudine | |||
| Yes | 17 | 28 | 0.5 |
| No | 15 | 36 | |
| Tenofovir | |||
| Yes | 15 | 35 | 0.6 |
| No | 17 | 29 | |
| Emtricitabine | |||
| Yes | 4 | 20 | 0.08 |
| No | 28 | 44 | |
| Emtricitabine+tenofovir | |||
| Yes | 4 | 20 | 0.08 |
| No | 28 | 44 | |
| Zidovudine+lamivudine | |||
| Yes | 7 | 11 | 0.8 |
| No | 25 | 53 | |
| Didanosine | |||
| Yes | 4 | 4 | 0.4 |
| No | 28 | 60 | |
| Abacavir | |||
| Yes | 3 | 4 | 0.6 |
| No | 29 | 60 | |
| Efavirenz | |||
| Yes | 11 | 20 | 0.9 |
| No | 21 | 44 | |
| Nevirapine | |||
| Yes | 3 | 6 | 1 |
| No | 29 | 58 | |
| Atazanavir | |||
| Yes | 6 | 16 | 0.6 |
| No | 26 | 48 | |
| Fosamprenavir | |||
| Yes | 2 | 2 | 0.6 |
| No | 30 | 62 | |
| Lopinavir/ritonavir | |||
| Yes | 2 | 5 | 1 |
| No | 30 | 59 | |
Indices of cardiovascular autonomic control
| LF/HF ratio | 2,78 ± 1,08 | 2,91 ± 1,23 | 0,306 |
| LF (n.u.) | 58, 48 ± 10,35 | 60,73 ± 9,68 | 0,151 |
| HF (n.u.) | 31,10 ± 7,43 | 30,72 ± 7,29 | 0,404 |
| LF/HF ratio day | 3,26 ±1,25 | 3,26 ± 1,43 | 0,491 |
| LF day (n.u.) | 62,91 ± 10,81 | 63,64 ± 10,81 | 0,378 |
| HF day (n.u.) | 26,85 ± 7,69 | 27,32 ± 7,26 | 0,385 |
| LF/HF ratio night | 1,90 ± 1,06 | 2,30 ± 1,14 | 0,050 |
| LF night (n.u.) | 50,30 ± 12,94 | 56,46 ± 10,41 | 0,007 |
| HF night (n.u.) | 38,76 ± 9,45 | 35,78 ± 9,46 | 0,077 |
| SDNN (ms) | 119,23 ± 38,64 | 122,93 ± 34,92 | 0,320 |
| SDNN day (ms) | 87,61 ± 25,14 | 97,26 ± 41,00 | 0,114 |
| SDNN night (ms) | 90,17 ± 27,66 | 104,22 ± 30,52 | 0,016 |
| RMSSD (ms) | 37,45 ± 14,74 | 40,49 ± 16,22 | 0,190 |
| RMSSD day (ms) | 36,16 ± 18,25 | 37,49 ± 16,00 | 0,358 |
| RMSSD night (ms) | 41,05 ± 18,00 | 43,23 ± 20,38 | 0,306 |
Results are expressed as mean ± SD for each variable. LF: low frequency; HF: high frequency; LF/HF: low frequency/high frequency; n.u.: normalized units; SDNN: standard deviation of all sinus rhythm RR intervals; RMSSD: the square root of the mean of the sum of the squares of differences between adjacent NN intervals; night time: 0–6 am, day time: 7 am–11 pm.